Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

EBMT 2023 | Key EBMT guideline updates for the treatment and prophylaxis of GvHD

Monia Marchetti • 26 Apr 2023

EBMT 2023

Monia Marchetti, MD, Azienda Ospedaliera SS. Antonio e. Biagio e Cesare Arrigo, Alessandria, Italy, shares the main guideline updates regarding the management and prevention of graft-versus-host disease (GvHD). In these guidelines, Prof. Marchetti addresses the use of ruxolitinib, ibrutinib, and belumosudil for steroid-refractory GvHD, as well as the prophylactic use of post-transplant cyclophosphamide (PTCy) in unrelated and mismatched donor transplants. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.